RxDoctor Payments Data

Navin Nakra, MD

Cardiovascular Disease · New York, NYNPI 1922258748

Payments from drug & device makers

$2,713in general payments, 2019–2025

Across 90 payments — averaging $30.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$902
  • Abbott$289
  • Abiomed$171
  • Shockwave Medical, Inc$143
  • Philips North America LLC$47
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$2,713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific48$1,125
Medtronic23$902
Abbott6$289
Abiomed2$171
Shockwave Medical, Inc7$143
Philips North America LLC2$47
Osprey Medical Inc1$20
Cardiovascular Systems Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,713 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$7,436
Medicare patients
85
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin20$12,455
Repatha SureclickEvolocumab15$11,357
PradaxaDabigatran Etexilate Mesylate36$8,490
EliquisApixaban11$3,732
Ranolazine ErRanolazine19$1,498
Atorvastatin Calcium101$1,469
ClopidogrelClopidogrel Bisulfate82$1,453
Flecainide Acetate25$930
Metoprolol Succinate71$828
Metoprolol Tartrate74$776
Losartan Potassium51$633
Amiodarone Hcl23$618
Lisinopril47$605
Carvedilol50$568
Amlodipine Besylate36$420

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →